Oncology Institute Inc. (TOI)
NASDAQ: TOI
· Real-Time Price · USD
3.30
0.04 (1.23%)
At close: Sep 05, 2025, 3:59 PM
3.45
4.55%
After-hours: Sep 05, 2025, 07:22 PM EDT
Oncology Institute Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capitated Revenue Revenue | 18.84M | 17.5M | 36.21M | 14.81M | 18.7M | 17.67M | 37.02M | 18.06M | 16.79M | 16.57M | 16.53M | 16.36M | 13.94M | 14.52M |
| Capitated Revenue Revenue Growth | +7.71% | -51.68% | +144.42% | -20.79% | +5.86% | -52.27% | +105.01% | +7.57% | +1.32% | +0.25% | +1.05% | +17.29% | -3.94% | n/a |
| Clinical Research Trials And Other Revenue Revenue | 1.34M | 2.04M | 4.14M | 1.94M | 1.68M | 2.53M | 3.62M | 1.61M | 1.6M | 1.68M | 1.82M | 1.51M | 1.59M | 1.43M |
| Clinical Research Trials And Other Revenue Revenue Growth | -34.57% | -50.60% | +113.51% | +15.62% | -33.82% | -29.98% | +124.92% | +0.44% | -4.59% | -8.00% | +20.78% | -5.21% | +11.86% | n/a |
| Dispensary Revenue Revenue | 62.57M | 49.29M | 92.03M | 48.21M | 44.44M | 39.68M | 54.4M | 26.79M | 25.2M | 24.24M | 21.61M | 18.84M | 20.22M | 18.68M |
| Dispensary Revenue Revenue Growth | +26.94% | -46.44% | +90.89% | +8.48% | +12.00% | -27.06% | +103.04% | +6.33% | +3.94% | +12.19% | +14.69% | -6.82% | +8.24% | n/a |
| Fee For Service Revenue | 37.05M | 35.57M | 66.47M | 34.94M | 33.76M | 34.79M | 72.79M | 35.58M | 36.64M | 33.7M | 31.47M | 28.27M | 25.16M | 20.54M |
| Fee For Service Revenue Growth | +4.15% | -46.48% | +90.25% | +3.50% | -2.95% | -52.21% | +104.59% | -2.90% | +8.71% | +7.12% | +11.30% | +12.35% | +22.51% | n/a |
| Health Care, Patient Service Revenue | 55.89M | 53.07M | 102.68M | 49.75M | 52.46M | 52.45M | 109.81M | 53.63M | 53.43M | 50.27M | 47.99M | 44.63M | 39.11M | 35.06M |
| Health Care, Patient Service Revenue Growth | +5.32% | -48.32% | +106.38% | -5.16% | +0.02% | -52.23% | +104.73% | +0.39% | +6.27% | +4.75% | +7.54% | +14.11% | +11.56% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 26.91M | 25.38M | 24.86M | 26.65M | 27.87M | 28.45M | 28.09M | 28.2M | 28.73M | 28.83M | 29.57M | 31.96M | 28.35M | 29.81M | 48.24M | 12.73M | 11.21M | 11.18M | 41.57M | 148.48K | 8.55M | 8.82M | 8.83M |
| Selling, General, and Administrative Revenue Growth | +6.03% | +2.08% | -6.71% | -4.40% | -2.04% | +1.29% | -0.41% | -1.81% | -0.36% | -2.51% | -7.48% | +12.75% | -4.89% | -38.22% | +278.99% | +13.54% | +0.31% | -73.11% | +27894.50% | -98.26% | -3.12% | -0.13% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |